Ampio Pharmaceuticals Announces Lifting of NYSE American Trading Halt

ENGLEWOOD, Colo., November 17, 2022 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE) (the “Company”) has received notice from NYSE American LLC (“NYSE American” or the “Exchange”) that NYSE personnel Regulation has withdrawn its delisting decision and will lift the suspension from trading in the Company’s common stock on the NYSE American.

Following the division by fifteen of the ordinary shares of the Company, which became effective November 9, 2022, NYSE Regulation staff determined that the company’s common stock was trading above the low sale price issue threshold, as further defined by NYSE American Company Section 1003(f)(v) Guide. As such, the Exchange has withdrawn its delisting decision and will lift the suspension from trading in the Company’s common stock on the NYSE American.

Ampio’s continued listing on the Exchange will be contingent upon proof of compliance with NYSE American Company Guide Section 1003(f)(v) for a period of at least December 232022. The Company will notify shareholders if and when it receives a notification from NYSE American that it has achieved compliance on this matter.

Ampio common stock will begin trading on the NYSE American on Tuesday, November 22, 2022 under the symbol “AMPE”.

Caution Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of current or historical facts, included in this document relating to the proposed stock consolidation and ‘strategic alternatives are forward-looking. – look at the statements. These forward-looking statements are subject to risks and uncertainties, including: the market price of Ampio common stock may not demonstrate sustained price improvement to regain compliance with NYSE American continuous listing standards during the period correction ending on December 23, 2022 or Ampio may not be able to maintain its listing on the NYSE American for any other reason.

Investor and media contacts:
Tony Russo or Nic Johnson
Russian partners
[email protected]
[email protected]
[email protected]

SOURCEAmpio Pharmaceuticals, Inc.

About Jason Norton

Check Also

NUWELLIS, INC. MANAGEMENT REPORT AND ANALYSIS OF FINANCIAL POSITION AND OPERATING RESULTS (Form 10-Q)

The following discussion and analysis of our financial condition and results of operations should be …